This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Fred Fleitz
Group Vice President, CMC at Arrowhead Pharmaceuticals
Speaker

Profile

Dr. Fleitz obtained his BS degree with a Chemistry major from Miami University in Oxford, Ohio. Upon completion of his studies there, he moved to Stanford University to pursue a doctoral degree under the direction of Professor Barry M Trost where his work included the development of palladium catalyzed reductive diyne cyclizations and the total synthesis of Siccanin. From Stanford, Dr. Fleitz moved to Merck and Co, in their Process Research department where he developed efficient, scaleable syntheses of small molecule drug candidates and was instrumental in the establishment of a biocatalysis group. After 14 years at Merck, Dr. Fleitz then moved to Cambridge Major Laboratories where he his work again focused on the process development of small molecules. In June of 2010 Dr. Fleitz moved to Arrowhead Research Corp., now Arrowhead Pharmaceuticals where he is currently the Group Vice President, Chemistry, Manufacturing, and Controls.

Agenda Sessions

  • Process Development Challenges for non-Hepatic Targeted siRNA Therapeutics

    14:30